Abstract: The present disclosure provides a superhydrophobic and self-cleaning anticoagulant composite coating material and a preparation method and use thereof, and relates to the technical field of biomedical materials. In the coating material provided by the present disclosure, a titanium dioxide nanotube-based structure increases microscopic roughness of a surface of a titanium-based metal substrate, and a hydrophobic modification layer reduces surface energy of the material. The rough structure and the hydrophobic modification layer have a synergistic effect to construct a superhydrophobic surface, making the surface of the material have self-cleaning characteristics and low adhesion. Air can be retained on the surface of the material to form an air layer, thereby reducing the contact area between the material and bacteria and platelets in the blood, and inhibiting adhesion of the bacteria, platelets, and plasma proteins to the material.

Abstract: Disclosed are a Nested Named Entity Recognition method based on part-of-speech awareness, system, device and storage medium therefor. The method uses a BiLSTM model to extract a feature of text word data in order to obtain a text word depth feature, and each text word of text to be recognized is initialized into a corresponding graph node, and a text heterogeneous graph of the text to be recognized is constructed according to a preset part-of-speech path, the text word data of the graph nodes is updated by an attention mechanism, and the features of all graph nodes of the text heterogeneous graph are extracted using the BiLSTM model, and a nested named entity recognition result is obtained after decoding and annotating. The present disclosure can recognize ordinary entities and nested entities accurately and effectively, and enhance the performance and advantages of the nested named entity recognition model.

Abstract: A method for analyzing a correlation between rail transit and direct current (DC) magnetic bias of a transformer includes the steps of, A: obtaining a current of a feed cable and a DC magnetic bias current: measuring the feed cable current in rail transit and the DC magnetic bias current of a transformer in a power grid within a certain period by a monitoring apparatus; B: calculating a characteristic quantity of the feed current within the measurement period based on the obtained current of the feed cable; C: calculating a characteristic quantity of the DC magnetic bias current within the measurement period based on the DC magnetic bias current; and D: calculating a support degree and a confidence coefficient based on the calculated characteristic quantity of the feed current and the calculated characteristic quantity of the DC magnetic bias current, and generating a correlation rule.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: Weigh-in-motion sensors comprise a beam including a plate with a load-bearing surface, and a tube portion including a base wall and a cover and defining a cavity therebetween. A sensing package is disposed within the cavity and is under pre-load with the cover and the base wall. The sensing package comprises a piezoelectric element. The base wall includes an aperture extending from a mounting surface to the cavity. The aperture includes a fastener therein to secure the sensing package within the cavity. The fastener is sized having a cross-section dimension taken through a center axis of the fastener that is greater than that of a cross-section dimension of the piezoelectric element taken along the fastener center axis. In an example, the fastener has a cross-section dimension sized about 10 percent or greater in dimension than that of the respective cross-section dimension of the piezoelectric element.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-L-R??(I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-L-R??(I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention discloses substituted pyrrolo[1,2-c]pyrimidines, such as the compound which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: A method for analyzing a correlation between rail transit and direct current (DC) magnetic bias of a transformer includes the following steps: A: obtaining a current of a feed cable and a DC magnetic bias current: measuring the feed cable current in rail transit and the DC magnetic bias current of a transformer in a power grid within a certain period by a monitoring apparatus; B: calculating a characteristic quantity of the feed current within the measurement period based on the obtained current of the feed cable; C: calculating a characteristic quantity of the DC magnetic bias current within the measurement period based on the DC magnetic bias current; and D: calculating a support degree and a confidence coefficient based on the calculated characteristic quantity of the feed current and the calculated characteristic quantity of the DC magnetic bias current, and generating a correlation rule.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-L-R??(I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: Weigh-in-motion sensors comprise a beam including a plate with a load-bearing surface, and a tube portion including a base wall and a cover and defining a cavity therebetween. A sensing package is disposed within the cavity and is under pre-load with the cover and the base wall. The sensing package comprises a piezoelectric element. The base wall includes an aperture extending from a mounting surface to the cavity. The aperture includes a fastener therein to secure the sensing package within the cavity. The fastener is sized having a cross-section dimension taken through a center axis of the fastener that is greater than that of a cross-section dimension of the piezoelectric element taken along the fastener center axis. In an example, the fastener has a cross-section dimension sized about 10 percent or greater in dimension than that of the respective cross-section dimension of the piezoelectric element.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-L-R??(I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-L-R??(I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.